Series B boost for ImCheck's gamma delta T cell therapies
ImCheck’s $53M series B will bring at least one T cell-activating antibody to the clinic, broaden immuno-oncology pipeline
With $53 million in series B funding, ImCheck plans to bring at least one of its T cell-activating antibodies into the clinic and broaden its immuno-oncology pipeline.
Pfizer Ventures and two Bpifrance funds, InnoBio 2 and Large Venture, led the round. Also joining were new investors Wellington Partners, Agent Capital, and Alexandria Venture Investments, along with existing investors LSP, Gimv, Idinvest